Infokiri

The mail below is being resent with a corrected URL to access ERVISS -  https://erviss.org/.  Many thanks to those of you who informed us the previous one was incorrect and please accept our apologies for the inconvenience.

To:        National Focal Points for Viral Respiratory Diseases, Operational Contact Points for COVID-19, Influenza and SARI  

Cc:       National Coordinators , National Focal Points for Surveillance

Dear colleagues,

A new and improved version of the European Respiratory Virus Surveillance Summary (ERVISS v2.0) is now available! Access it at https://erviss.org/

There are several new visualisations across ERVISS:

• Updated weekly summary of the epidemiological/virological situation for Influenza, SARS-CoV-2 and RSV

• New country section - a single page providing the user with an overview of the main indicators submitted by each country, together with a table describing the underlying national surveillance systems used to collect these data.

• RSV type data is now shown where reported. This is visible when only RSV is selected.

• More age-specific data is now shown especially for primary care surveillance data. These additional visualisations are possible due to the countries switching to reporting age-specific data to RESPIAGGR. This is visible when a single pathogen is selected.

• More detailed age distributions of hospitalised patients with SARI (severe acute respiratory infection) testing positive for Influenza, SARS-CoV-2 and RSV are shown in a new tab (‘Severity’ section 🡪 'SARI virological in detail' tab).

• Antiviral susceptibility data for influenza viruses are now be included.

• Additional heatmaps showing the relative contribution of weekly data by country. This is visible when a single pathogen is selected. 

In addition to the new visualisations, the following improvements have been implemented:

• Updated nomenclature for the different surveillance systems in the Methods, tab headings and introductions to better reflect the way in which data are collected in across different EU/EEA countries. (We will update to reflect WHO/EURO countries and areas)

• Updated calculation for influenza dominant type means this information is available for a greater number of weeks, including when influenza activity is lower.

• Narrowed time range of data to the current season plus four historical seasons to speed up and simply display of historical data.

Please remember to use the selection buttons on ERVISS to access all the new visualisations (e.g. pathogen selector, age selector). Some detailed plots are only visible when a single pathogen is selected.

Kind regards,

The ECDC and WHO Europe Respiratory Viruses Teams

To:        National Focal Points for Viral Respiratory Diseases, Operational Contact Points for COVID-19, Influenza and SARI  

Cc:       National Coordinators , National Focal Points for Surveillance

Dear colleagues,

A new and improved version of the European Respiratory Virus Surveillance Summary (ERVISS v2.0) is now available! Access it at erviss.org.

There are several new visualisations across ERVISS:

• Updated weekly summary of the epidemiological/virological situation for Influenza, SARS-CoV-2 and RSV

• New country section - a single page providing the user with an overview of the main indicators submitted by each country, together with a table describing the underlying national surveillance systems used to collect these data.

• RSV type data is now shown where reported. This is visible when only RSV is selected.

• More age-specific data is now shown especially for primary care surveillance data. These additional visualisations are possible due to the countries switching to reporting age-specific data to RESPIAGGR. This is visible when a single pathogen is selected.

• More detailed age distributions of hospitalised patients with SARI (severe acute respiratory infection) testing positive for Influenza, SARS-CoV-2 and RSV are shown in a new tab (‘Severity’ section 🡪 'SARI virological in detail' tab).

• Antiviral susceptibility data for influenza viruses are now be included.

• Additional heatmaps showing the relative contribution of weekly data by country. This is visible when a single pathogen is selected. 

In addition to the new visualisations, the following improvements have been implemented:

• Updated nomenclature for the different surveillance systems in the Methods, tab headings and introductions to better reflect the way in which data are collected in across different EU/EEA countries. (We will update to reflect WHO/EURO countries and areas)

• Updated calculation for influenza dominant type means this information is available for a greater number of weeks, including when influenza activity is lower.

• Narrowed time range of data to the current season plus four historical seasons to speed up and simply display of historical data.

Please remember to use the selection buttons on ERVISS to access all the new visualisations (e.g. pathogen selector, age selector). Some detailed plots are only visible when a single pathogen is selected.

Kind regards,

The ECDC and WHO Europe Respiratory Viruses Teams

DC NORMAL